Danielle Showalter

Danielle Showalter advises clients on reimbursement, policy, and market access strategies for diagnostic, medical device, and pharmaceutical companies.

Danielle provides a rich background in consulting and research services, particularly in the areas of physician payment, CPT® coding, device reimbursement strategies, and diagnostic payment policy.

Prior to Avalere, Danielle was the director of Health Policy and Reimbursement at ADVI, assisting diagnostic and device clients in developing and implementing coding, coverage, and reimbursement strategies as well as understanding the impact of regulatory and legislative changes. Danielle also worked for Altarum Institute, providing research support, expertise, and primary IRB review for TRICARE.

Danielle has an MA in public health from the George Washington University and a BA from the University of Virginia.

Authored Content

Mitigating the public health emergency (PHE) caused by SARS-CoV-2 requires a multifaceted approach.

On June 11, Avalere experts explored the future of telehealth and how organizations can help shape and take advantage of its increased utilization.

Avalere experts explored the future role of telehealth and how organizations can help shape and take advantage of its increased utilization.

As the novel coronavirus (COVID-19) spreads throughout the United States, media and policy focus on the rollout of diagnostic testing for the disease has greatly increased. Understanding the role of testing and screening is key to the control of this outbreak.

New flexibilities for telehealth services in fee-for-service (FFS) Medicare are designed to support ongoing COVID-19 response efforts.

Tune into the second episode of our podcast series that focuses on COVID-19. In episode 2, Avalere experts discuss how Medicare, Medicaid, and commercial plans will address the patient out of pocket costs associated with COVID-19 testing and treatment. They also acknowledge how commercial manufacturers are addressing the shortage of tests and turnaround for COVID-19 testing in the US.

Tune in to hear the second episode in our 3-part series that focuses on CMS’s most recent proposed payment rules. In episode 2, we’ll be focusing on the Medicare Physician Fee Schedule proposed rule, or MPFS, with a focus on proposed changes to E/M and Opioid Use Disorder (OUD) treatment services.

While precision medicine is expected to revolutionize patient therapy, the increasing complexity of diagnostics is leading policymakers to revamp the way these tests are regulated and paid for.

Last Tuesday, August 2, the Centers for Medicare & Medicaid Services (CMS) released the FY 2017 IPPS final rule